Joana Goncalves, serving as the Chief Medical Officer for Oruka Therapeutics, Inc. (NASDAQ: ORKA), has filed reports detailing recent transactions in the company's common stock. The filings indicate that on June 15, 2026, Goncalves executed a series of sales totaling approximately $550,606. Concurrently, the executive acquired shares valued at $51,240 through the exercise of employee stock options and warrants.
The sales activity comprised a total of 7,947 shares of Oruka Therapeutics common stock. These shares were divested at prices ranging between $68.3839 and $70.6233 per share. A substantial portion of these sales, specifically 7,000 shares, was carried out under a Rule 10b5-1 trading plan that was originally established on September 19, 2025. The remaining 947 shares were sold through Oruka Therapeutics’ automatic, non-discretionary, sell-to-cover procedure. This mechanism was utilized to satisfy tax withholding obligations associated with the vesting of restricted stock units.
Alongside the sales, Goncalves acquired 7,000 shares of common stock by exercising employee stock options and warrants. The acquisition prices for these shares ranged from $6.84 to $7.80 per share. Following the completion of these transactions, Goncalves holds a direct position of 32,718 shares of Oruka Therapeutics common stock. This total ownership figure includes 288 shares that were acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026.
In parallel with the insider activity, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001. The trial focused on treating moderate-to-severe plaque psoriasis and demonstrated promising efficacy. Specifically, 63.5% of participants achieved complete clearance of psoriasis plaques at Week 16. The company also priced a public offering of 9,660,000 shares at $72.50 per share. This offering aims to raise approximately $700.4 million in gross proceeds, reflecting the company’s strategy to bolster its financial position for future developments.
Additionally, Oruka amended its license agreement with Paragon Therapeutics. This amendment allows for expanded rights for IL-23 treatments. The change opens new opportunities for combination and monotherapy developments. Analysts have responded to these developments with updated ratings. H.C. Wainwright reiterated a Buy rating with a $120 price target for Oruka, citing the positive trial data. Piper Sandler also maintained an Overweight rating with a $180 price target, following the license agreement changes. These analyst ratings highlight confidence in Oruka’s potential growth and development.